Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6590528rdf:typepubmed:Citationlld:pubmed
pubmed-article:6590528lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:6590528lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:6590528lifeskim:mentionsumls-concept:C0014582lld:lifeskim
pubmed-article:6590528pubmed:issue1lld:pubmed
pubmed-article:6590528pubmed:dateCreated1984-9-21lld:pubmed
pubmed-article:6590528pubmed:abstractTextThe pharmacokinetics of 4'-epi-doxorubicin (4'-epi-adriamycin, 4'-epi-DX) in man can be described by a three-compartment model with a rapid distribution phase and a very long elimination phase. Urine excretion amounts to a total of about 11% of the administered dose during 48 h after drug administration, and less than 1% during the following 48 h. In plasma 4'-epi-doxorubicin is rapidly converted to five metabolites (4'-epi-doxorubicinol, aglycones and glucuronides), the concentration of the aglycones sometimes exceeding that of 4'-epi-DX. In urine only three metabolites were found in addition to the parent drug; they were identified as 4'-epi-doxorubicinol (EOH), 4'-epi-doxorubicin-glucuronide (E-Glu) and 4'-epi-doxorubicinol-glucuronide (EOH-Glu). Comparison of the pharmacokinetics and metabolic profiles of 4'-epi-DX and doxorubicin (DX) in man revealed that 4'-epi-DX eliminates faster than DX.lld:pubmed
pubmed-article:6590528pubmed:languageenglld:pubmed
pubmed-article:6590528pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6590528pubmed:citationSubsetIMlld:pubmed
pubmed-article:6590528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6590528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6590528pubmed:statusMEDLINElld:pubmed
pubmed-article:6590528pubmed:issn0167-6997lld:pubmed
pubmed-article:6590528pubmed:authorpubmed-author:PinedoH MHMlld:pubmed
pubmed-article:6590528pubmed:authorpubmed-author:McVieJ GJGlld:pubmed
pubmed-article:6590528pubmed:authorpubmed-author:LankelmaJJlld:pubmed
pubmed-article:6590528pubmed:authorpubmed-author:WeenenHHlld:pubmed
pubmed-article:6590528pubmed:authorpubmed-author:ten Bokkel...lld:pubmed
pubmed-article:6590528pubmed:authorpubmed-author:de PlanqueM...lld:pubmed
pubmed-article:6590528pubmed:authorpubmed-author:PendersP GPGlld:pubmed
pubmed-article:6590528pubmed:issnTypePrintlld:pubmed
pubmed-article:6590528pubmed:volume1lld:pubmed
pubmed-article:6590528pubmed:ownerNLMlld:pubmed
pubmed-article:6590528pubmed:authorsCompleteYlld:pubmed
pubmed-article:6590528pubmed:pagination59-64lld:pubmed
pubmed-article:6590528pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6590528pubmed:meshHeadingpubmed-meshheading:6590528-...lld:pubmed
pubmed-article:6590528pubmed:meshHeadingpubmed-meshheading:6590528-...lld:pubmed
pubmed-article:6590528pubmed:meshHeadingpubmed-meshheading:6590528-...lld:pubmed
pubmed-article:6590528pubmed:meshHeadingpubmed-meshheading:6590528-...lld:pubmed
pubmed-article:6590528pubmed:meshHeadingpubmed-meshheading:6590528-...lld:pubmed
pubmed-article:6590528pubmed:meshHeadingpubmed-meshheading:6590528-...lld:pubmed
pubmed-article:6590528pubmed:year1983lld:pubmed
pubmed-article:6590528pubmed:articleTitlePharmacokinetics of 4'-epi-doxorubicin in man.lld:pubmed
pubmed-article:6590528pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6590528pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:6590528pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6590528lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6590528lld:pubmed